कंपनी का अवलोकन
Xilio Therapeutics, Inc. is a clinical-stage biotechnology entity dedicated to the discovery and development of tumor-activated immuno-oncology therapies, specifically focusing on checkpoint inhibitor programs like XTX101. The company operates within the Healthcare sector, functioning as a specialized player in the Biotechnology industry where innovation drives the creation of novel treatments for complex diseases. Its operational scale is defined by a market capitalization of $50.25M, an annual revenue of $43.77M, and a workforce comprising 76 employees. These financial metrics indicate that Xilio Therapeutics maintains a mid-sized valuation relative to its revenue generation, suggesting a firm that has achieved significant revenue expansion while still operating with a relatively lean internal team typical of clinical-stage entities.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $43.77M, yet it recorded a net income of $-35,036,000 and an EBITDA of $-40,441,000, revealing a substantial gap between top-line generation and bottom-line profitability due to high operational expenses inherent in drug development. Despite the reported losses in net income and EBITDA, the entity generated positive free cash flow of $8.03M, which provides a critical buffer for financial flexibility and operational continuity without immediate reliance on external financing. The company demonstrates exceptional gross margin performance at 100.0%, indicative of a cost structure where the cost of goods sold is negligible compared to sales, while the operating margin of -86.5% and profit margin of -80.1% highlight the significant investment in research, development, and administrative overhead required to advance clinical trials. On the balance sheet, Xilio Therapeutics holds $137.53M in cash against $6.95M in debt, resulting in a conservative leverage profile underscored by a debt-to-equity ratio of 19.71. The current ratio stands at 2.58, signaling strong short-term liquidity and the ability to meet obligations as they come due without distress. Furthermore, the return on equity is -132.5% and the return on assets is -23.2%, metrics that reflect the capital-intensive nature of the business where current management efforts are directed toward growth initiatives rather than generating immediate shareholder returns.
मूल्यांकन आकलन
Valuation metrics for Xilio Therapeutics show a trailing P/E ratio of N/A and a forward P/E of -14.98, implying that the market prices the stock based on future expected earnings normalization rather than current profitability. The price-to-book ratio is recorded at 1.12, suggesting that the market values the company slightly above its book value, potentially reflecting the intangible value of its intellectual property and clinical pipeline. Alternative valuation measures include a price-to-sales ratio of 1.15 and an EV/EBITDA of 1.99, which provide a normalized view of the company's worth relative to its revenue generation and enterprise value despite current losses. The stock has traded between a 52-week high of $16.52 and a 52-week low of $6.47, placing the current trading range within a wide band that reflects the volatility typical of clinical-stage biotech firms. The beta value is -0.12, an anomalous figure that indicates the stock's price movements are inversely correlated or have very low correlation with the broader market index compared to the typical positive beta of most equities.
Growth & Income
Xilio Therapeutics experienced a revenue growth rate of 693.9% year-over-year, while earnings growth is marked as N/A due to the absence of positive net income in the comparable period. This disparity implies that the company is prioritizing revenue expansion through rapid market uptake or commercialization of its therapies over immediate earnings generation, a common strategy in the early commercial phases of biotechnology. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings and cash reserves are reinvested directly into research, development, and clinical trial advancements rather than shareholder distributions. The overall growth and income profile characterizes Xilio Therapeutics as a high-potential, high-risk asset that offers substantial revenue scalability but currently lacks a dividend income stream for investors seeking passive cash returns.